Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Current Assets: 2015-2025

Historic Current Assets for Spyre Therapeutics (SYRE) over the last 10 years, with Sep 2025 value amounting to $504.6 million.

  • Spyre Therapeutics' Current Assets rose 19.84% to $504.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $504.6 million, marking a year-over-year increase of 19.84%. This contributed to the annual value of $608.5 million for FY2024, which is 78.16% up from last year.
  • Per Spyre Therapeutics' latest filing, its Current Assets stood at $504.6 million for Q3 2025, which was down 6.35% from $538.8 million recorded in Q2 2025.
  • Spyre Therapeutics' Current Assets' 5-year high stood at $608.5 million during Q4 2024, with a 5-year trough of $44.4 million in Q1 2023.
  • Over the past 3 years, Spyre Therapeutics' median Current Assets value was $435.7 million (recorded in 2024), while the average stood at $399.8 million.
  • In the last 5 years, Spyre Therapeutics' Current Assets tumbled by 52.05% in 2022 and then surged by 998.08% in 2024.
  • Quarterly analysis of 5 years shows Spyre Therapeutics' Current Assets stood at $98.9 million in 2021, then plummeted by 37.04% to $62.3 million in 2022, then surged by 448.57% to $341.5 million in 2023, then soared by 78.16% to $608.5 million in 2024, then climbed by 19.84% to $504.6 million in 2025.
  • Its Current Assets was $504.6 million in Q3 2025, compared to $538.8 million in Q2 2025 and $569.8 million in Q1 2025.